Skin cancer is the most common type of malignancy in the United States, and its morbidity continues to rise. In recent decades, the establishment of accountable care organizations has shifted the paradigm of physician compensation to a basis in performance measures. Given the profound economic burden of skin cancer, the accuracy of its diagnosis has the potential to be a useful performance measure. One way to evaluate diagnostic accuracy is to calculate the number needed to biopsy (NNB), or the number of biopsies needed to detect 1 skin cancer.
Shahwan KT, Kimball AB. Should We Leave the Skin Biopsies to the Dermatologists?. JAMA Dermatol. 2016;152(4):371-372. doi:10.1001/jamadermatol.2015.5051